The reading behind the guide
Where our facts come from.
This page explains the sources behind Lumira's descriptions of skin peptides and U.S. rules. Sources answer specific questions. A naming record, a research review and a drug approval are different kinds of evidence.
Licensed U.S. provider review
Start Promise Peptides skin visitLumira may earn money when readers become Promise patients.
Promise prescribes GHK-Cu, Glow and KLOW now through licensed U.S. providers. A provider reviews every request and decides whether a prescription is appropriate. Not everyone qualifies. Compounded medicines are made to order. They are not approved by the U.S. Food and Drug Administration (FDA).
U.S. patients only. Availability varies by state and by treatment.
Read for the question it can answer
The U.S. Food and Drug Administration, or FDA, is the source for the regulatory distinctions in this guide. We use its records to explain compounding, cosmetics and the entries listed as “nominated but withdrawn.”
Those records are not interchangeable. A cosmetic ingredient's history does not establish injectable safety. A substance name appearing in a record does not mean an approved drug exists.
We use compound reviews for identity and research limits. We keep work on cells, animals and people separate. Research on one ingredient does not establish what a blend does, and a fragment is different from the full peptide it comes from.
Five starting points
These sources support the guide's core distinctions. The compound pages also link to the records behind their specific research discussions.
- FDA's peptide safety concerns and withdrawn requestsU.S. Food and Drug Administration
The injectable GHK-Cu, BPC-157, TB-500 and KPV entries sit in the withdrawn-request table. Their safety concerns remain listed. The page gives no individual withdrawal dates.
- FDA's questions and answers about compoundingU.S. Food and Drug Administration
Compounding means preparing a medicine to order. Compounded medicines are not FDA-approved; FDA does not review them for safety, effectiveness or quality before sale.
- How FDA rules for cosmetics differ from drug rulesU.S. Food and Drug Administration
Most cosmetics do not need FDA approval before sale. A cosmetic and a drug have different rules, and the claims made about a product matter to that distinction.
- FDA's separate category entry for non-injected GHK-CuU.S. Food and Drug Administration · List updated May 14, 2026
Non-injected GHK-Cu has a separate Category 1 entry. This describes a limited enforcement policy subject to conditions while review continues, not approval.
- A research review of topical GHKMortazavi and colleagues · Bioimpacts, 2025 · PMID 39963574
This review concerns GHK in products placed on the skin and the questions around getting it through the skin's outer layer. It does not establish injectable safety.
Dates describe a record, not a prediction
The FDA safety page used here is current as of April 22, 2026. That is the page's date, not a date for any individual peptide's withdrawal. The separate category list is updated May 14, 2026.
Withdrawn requests are not clearance or approval for compounding. Non-injected GHK-Cu has a separate Category 1 entry; it does not include injectable GHK-Cu. No future FDA decision is assumed in these pages.
The guide's date is October 8, 2026. A dated explanation does not promise that a rule or service will stay the same.
The next page is yours
Keep the licensed route in view
A visit begins a review. A licensed U.S. provider decides whether a prescription is appropriate. Not everyone qualifies, and availability varies by state and by treatment.
Licensed U.S. provider review
Start Promise skin visitLumira may earn money when readers become Promise patients.
Promise prescribes GHK-Cu, Glow and KLOW now through licensed U.S. providers. A provider is a health professional who can make prescription decisions. One reviews every request and decides whether to prescribe. Not everyone qualifies.
Medications are prepared by licensed U.S. compounding pharmacies. Compounded medications are not FDA-approved. A pharmacy separately decides whether it can lawfully prepare a prescription.
U.S. patients only. Availability varies by state and by treatment.
Promise is LegitScript-certified. That certification is not FDA approval.